iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2016
Exchange: NASDAQ
Website: irhythmtech.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
7/19/2023 | $130.00 | Outperform | Robert W. Baird |
2/7/2023 | $150.00 | Overweight | Wells Fargo |
11/7/2022 | Underperform → Peer Perform | Wolfe Research | |
6/9/2022 | $180.00 → $155.00 | Buy → Neutral | Citigroup |
4/6/2022 | $105.00 | Underperform | Wolfe Research |
2/24/2022 | $167.00 → $151.00 | Overweight | Morgan Stanley |
2/24/2022 | Hold → Buy | Needham | |
2/24/2022 | $135.00 | Hold → Buy | Needham |
SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM). "As a natural complement to iRhythm's leading ambulatory cardiac monitoring platform, BioIntelliSense's multiparameter sensing technologies position us to significantly expand the capabilities of our product p
GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024Leveraging iRhythm's Zio® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm's Zio® XT1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual care in the context of reduced statistical power due to truncated enrollment and follow-up. SAN FRANCISCO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital heal
Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization Software) System (iRhythm's advanced AI algorithm), and a comprehensive end-of-wear report reviewed and curated by certified cardiographic technicians.The next-generation Zio monitor LTCM provides up to 14 days of continuous, uninterrupted, patch-based ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour (Holter) monitoring technology1. Zio LTCM is associated with a greater diagnostic yield of specified arrhythmias, the lowest likelihood of retesting
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern TimeWells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern TimeBaird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time Those interested in listening to the presentations may do so by accessing the live and archived webcast
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm's current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition. "Brice has been an outstanding leader at iRhythm over
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023Unrestricted cash, cash equivalents and marketable securities of $561.5 million as of June 30, 2024Increased fiscal year 2024 guidance for revenue, gross margin, and adjusted EBITDA Recent Operational Highlights R
SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadi
SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings. In this initial phase, iRhythm has implemented a cutting-edge autohandler machine to automate the testing of printed circuit board assembly (PCBA) components of the recently-launched Zio monitor. This a
SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference. iRhythm's management is scheduled to participate in a fireside chat on Tuesday, June 18, at 9:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health care company that
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming William Blair 44th Annual Growth Stock Conference. iRhythm's management is scheduled to present on Wednesday, June 5, at 11:20 a.m. Central Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health care company that cr
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
SD - iRhythm Technologies, Inc. (0001388658) (Filer)
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
ARS - iRhythm Technologies, Inc. (0001388658) (Filer)
DEFA14A - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
Wolfe Research upgraded iRhythm from Peer Perform to Outperform and set a new price target of $115.00
Citigroup upgraded iRhythm from Neutral to Buy and set a new price target of $110.00
Robert W. Baird initiated coverage of iRhythm with a rating of Outperform and set a new price target of $130.00
Wells Fargo initiated coverage of iRhythm with a rating of Overweight and set a new price target of $150.00
Wolfe Research upgraded iRhythm from Underperform to Peer Perform
Citigroup downgraded iRhythm from Buy to Neutral and set a new price target of $155.00 from $180.00 previously
Wolfe Research initiated coverage of iRhythm with a rating of Underperform and set a new price target of $105.00
Morgan Stanley reiterated coverage of iRhythm Technologies with a rating of Overweight and set a new price target of $151.00 from $167.00 previously
Needham upgraded iRhythm from Hold to Buy
Needham upgraded iRhythm Technologies from Hold to Buy and set a new price target of $135.00
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company's Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in sup
SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) ("iRhythm"), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Karen Ling, an experienced HR leader, to its Board of Directors effective November 1, 2021. Ms. Ling was appointed as a Class 1 Director. The company also announced the retirement of Raymond Scott from the Board, effective November 1, 2021. Mr. Scott joined the iRhythm Board in 2013. "On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors," said Quentin Blackford, iRhythm President and CEO. "Karen is a renowned HR leader in t
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire as President and CEO effective January 12, 2021. Mr. King will continue to serve on iRhythm's board of directors and as an advisor to the business. Effective the same date, Mike Coyle will join the company as President and CEO and as a member of its board of directors. Under King’s leadership, iRhythm successfully completed an IPO in 2016, achieved record financial growth and increased shareholder value significantly. During his tenure, the company’s annual revenue
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023Unrestricted cash, cash equivalents and marketable securities of $561.5 million as of June 30, 2024Increased fiscal year 2024 guidance for revenue, gross margin, and adjusted EBITDA Recent Operational Highlights R
SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadi
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023Unrestricted cash, cash equivalents and marketable securities of $569.1 million as of March 31, 2024Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million Recent Opera
SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading
SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Grew fourth quarter 2023 patient registrations in excess of 22% compared to the fourth quarter 2022Revenue of $132.5 million, a 17.7% increase compared to fourth quarter 2022Gross margin of 66.0%, a 390 basis point decrease compared to fourth quarter 2022Net loss of $38.7 million, an $18.5 million increased loss compared to fourth quarter 2022Adjuste
SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2023 after the close of trading on Thursday, February 22, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. i
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenue of $124.6 million, a 20.0% increase compared to third quarter 2022Gross margin of 66.2%, a 210-basis point decline compared to third quarter 2022Cash, cash equivalents and marketable securities of $158.5 million as of September 30, 2023Increased fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million Recent Operational High
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2023 after the close of trading on Thursday, November 2, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the investors section of the Company's website at investors.irhythmtech.com. About iRhythm Techn
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Financial Results Revenue of $124.1 million, a 21.6% increase compared to second quarter 2022Gross margin of 69.5%, a 70-basis point improvement compared to second quarter 2022Cash, cash equivalents and marketable securities of $164.7 million as of June 30, 2023Updated fiscal year 2023 revenue guidance in a range of approximately $485 million to $490 million Recent Operational Hi
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2023 after the close of trading on Thursday, August 3, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the investors section of the Company's website at investors.irhythmtech.com. About iRhythm Techno
5 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:IRTC) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $127.8, with a high estimate o
Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $145 to $134.
Morgan Stanley analyst Cecilia Furlong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and lowers the price target from $135 to $130.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week’s release of ‘San Guo: Mou Ding Tian Xia.’ Also, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price forecast. ImmunityBio, Inc. (NASDAQ:IBRX) shares jumped 22.36% on continued strength after the announcement of insurance coverage of ANKTIVA across multiple states with the first commercial doses administered. Sasol Ltd. (NYSE:SSL) shares escalated 20.89% after the company announced that the court ruled in favor of the company and TotalEnergies SE (NYSE:TTE) Marketing. Also, it
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wolfe Research analyst Mike Polark upgraded the rating for iRhythm Technologies, Inc. (NASDAQ:IRTC) from Peer Perform to Outperform and announced a price target of $115. iRhythm Technologies shares gained 2.5% to close at $98.16 on Wednesday. See how other analysts view this stock. Evercore ISI Group analyst John Pancari upgraded Bread Financial Holdings, Inc. (NYSE:BFH) from Underperform to In-Line and boosted the price target from $42 to $45. Bread Finl shares gained 0.5% to close at
Wolfe Research analyst Mike Polark upgrades iRhythm Technologies (NASDAQ:IRTC) from Peer Perform to Outperform and announces $115 price target.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study met primary endpoint. Several analysts raised their forecasts after the announcement. Verint Systems Inc. (NASDAQ:VRNT) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results and issued strong FY25 guidance. Novavax Inc (NASDAQ:NVAX) shares gained 21.54% in the last week after the U.S. Food and Drug Administration’s advisory committee voted to recommend updated vaccines for JN.1-line